These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group. Am J Cardiol; 2007 Dec 01; 100(11):1659-64. PubMed ID: 18036365 [Abstract] [Full Text] [Related]
24. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H, Müller-Nordhorn J. Eur J Cardiovasc Prev Rehabil; 2009 Apr 01; 16(2):180-7. PubMed ID: 19174696 [Abstract] [Full Text] [Related]
33. Rosuvastatin in patients with elevated C-reactive protein. Chan PS, Nallamothu BK, Hayward RA. N Engl J Med; 2009 Mar 05; 360(10):1039; author reply 1041-2. PubMed ID: 19271273 [No Abstract] [Full Text] [Related]
34. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Cardiology; 2007 Mar 05; 107(4):433-43. PubMed ID: 17363845 [Abstract] [Full Text] [Related]